Related Experiment Video

Updated: Jan 12, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

895

Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?

Donal J Brennan1,2, Lydia Lynch3,4

  • 1UCD Gynaecological Oncology Group, UCD School of Medicine, Mater Misericordiae University Hospital, Dublin, Ireland.

Cancer Discovery
|November 3, 2025
PubMed

Insights

Glucagon-like peptide 1 receptor agonists show promise in reducing cancer risk for individuals with obesity. Further research is needed to fully understand their mechanisms and potential in cancer prevention.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Obesity is a significant risk factor for various cancers.
  • Glucagon-like peptide 1 receptor (GLP-1R) agonists are established antiobesity medications.
  • Emerging evidence suggests a potential role for GLP-1R agonists in cancer risk reduction.

Purpose of the Study:

  • To review the current evidence on the impact of GLP-1R agonists on cancer risk in obesity.
  • To explore the underlying mechanisms linking GLP-1R agonism to cancer prevention.
  • To identify areas requiring further investigation in the field of antiobesity medicines and cancer.

Main Methods:

  • Systematic review of preclinical studies (in vitro and animal models).
  • Analysis of emerging clinical trial data.
  • Evaluation of human observational studies and clinical caveats.

Main Results:

  • Preclinical data and early clinical trials suggest GLP-1R agonists may reverse certain cancer risks associated with obesity.
  • Mechanisms may involve direct effects on cancer cells or indirect effects via metabolic improvements.
  • Caveats from human studies indicate a need for more comprehensive research.

Conclusions:

  • GLP-1R agonists represent a promising therapeutic avenue for mitigating cancer risk in obese populations.
  • Understanding the precise mechanisms and long-term effects is crucial for optimizing their use in cancer prevention.
  • Continued research is essential to fully elucidate the role of antiobesity medications in oncology.

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.3K
Segmentation and Measurement of Fat Volumes in Murine Obesity Models Using X-ray Computed Tomography13:09

Segmentation and Measurement of Fat Volumes in Murine Obesity Models Using X-ray Computed Tomography

Published on: April 4, 2012

16.5K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
832
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
233
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
571
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
164
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
574